The Indian Patent Office has rejected American drug maker Pfizer's patents for its rheumatoid arthritis drug tofacitinib in India.
“After having considered the submissions submitted by the applicant (Pfizer) in the hearing, the written submission and amended claims filed as well as in view of the discussions and findings by me, it is hereby ordered that the invention disclosed and claimed in the instant application is not considered as an invention under the provisions of the Act”, said Bharat N S, assistant controller of patents & designs, Mumbai.